Drug Insights

Master Dextromethorphan Search on Synapse

27 February 2024
2 min read

Dextromethorphan (DXM) is a synthetic analog of codeine, but unlike codeine, it is not a narcotic and does not have the same potential for abuse or addiction. DXM is an N-methyl-D-aspartate (NMDA) receptor antagonist, NMDA receptors are involved in pain perception and the regulation of mood, learning, and memory. DXM is a sigma-1 receptor agonist,Sigma-1 receptors are involved in many different functions, including pain perception, mood regulation, and neuroprotection. Dextromethorphan is commonly used as a cough suppressant, and it has also been investigated for its potential therapeutic effects in a variety of conditions, including neuropathic pain, depression, and addiction. Dextromethorphan was successfully tested in 1954 as part of US Navy and CIA-funded research on nonaddictive substitutes for codeine. It was approved by the FDA in 1958 as an over-the-counter antitussive. Click on the image below to begin the exploration journey of Dextromethorphan through the Synapse database!

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

You can search for the latest pharmaceutical information such as drugs, targets, patents, transactions, clinical results, etc. through the Synapse database. Come and experience it!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

FDA Approves Biweekly TECVAYLI® for Refractory Multiple Myeloma
Latest Hotspot
3 min read
FDA Approves Biweekly TECVAYLI® for Refractory Multiple Myeloma
27 February 2024
FDA has sanctioned a biweekly administration of TECVAYLI® (teclistamab-cqyv) as a therapeutic option for those suffering from recurring or unresponsive multiple myeloma.
Read →
Exploring the Latest new anti-obesity drugs Deal by EraCal Therapeutics: A Guide to Rapidly Accessing Transaction Insights
DrugDeal Decode
3 min read
Exploring the Latest new anti-obesity drugs Deal by EraCal Therapeutics: A Guide to Rapidly Accessing Transaction Insights
27 February 2024
On January 24, 2024, Novo Nordisk partnered with EraCal Therapeutics to co-develop an appetite and weight control drug.
Read →
Polpharma Biologics' Biosimilar Matches Entyvio® in Pharmacokinetics and Dynamics Study
Latest Hotspot
3 min read
Polpharma Biologics' Biosimilar Matches Entyvio® in Pharmacokinetics and Dynamics Study
27 February 2024
The experimental biosimilar by Polpharma Biologics demonstrates similar pharmacokinetics and dynamics to the top-selling IBD medication, Entyvio®.
Read →
Unveiling Acyclovir: How to Search for it on Synapse
Drug Insights
2 min read
Unveiling Acyclovir: How to Search for it on Synapse
27 February 2024
Acyclovir, sold as ZOVIRAX, is a synthetic drug that inhibits herpes viruses, including HSV-1, HSV-2, and VZV, both in lab and living organisms.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.